Market Place
Sourcing Support
Neurophet And AriBio Partner For Next-Gen Alzheimer’s Diagnosis
15 Oct 2024 //
CONTRACTPHARMA
Adaptive Research Begins Enrollment In AriBio`s POLARIS-AD Trial
30 Sep 2024 //
GLOBENEWSWIRE
AriBio And Fujirebio Advance Alzheimer`s Biomarker Development
15 Jul 2024 //
BUSINESSWIRE
AriBio Announces Collaboration with KCTL for Alzheimer’s Testing
21 Jun 2024 //
BUSINESSWIRE
AriBio Receives China IND Approval For Alzheimer`s POLARIS-AD Phase 3
14 May 2024 //
BUSINESSWIRE
AriBio EMA Phase 3 Trial Authorisation For AR1001 in Alzheimer`s (POLARIS-AD)
28 Apr 2024 //
BUSINESSWIRE
AriBio Licenses Exclusive Marketing Rights for AR1001 for AD in China for $770M
24 Mar 2024 //
BUSINESSWIRE
MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Alzheimer’s Trial
25 Feb 2024 //
BUSINESSWIRE
AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD
14 Nov 2023 //
BUSINESSWIRE
AriBio to Present Biomarker Data for AR1001 Alzheimer’s Disease Phase 2 Study
31 Mar 2023 //
BUSINESSWIRE
AriBio and Fujirebio Announce Partnership to Advance Biomarker Development
08 Mar 2023 //
BUSINESSWIRE
First Participants Enrolled in AriBio PIII Trial to Evaluate AR1001
05 Jan 2023 //
BUSINESSWIRE
AriBio Successfully Completes End of Phase 2 Meeting With the USFDA
04 May 2022 //
BUSINESSWIRE
The Potential of AriBio’s AR1001, Confirmed in a Recent Independent Study
20 Dec 2021 //
BUSINESSWIRE
Huons, AriBio to develop new brain disease drugs targeting global market
23 Sep 2021 //
KOREABIOMED
AriBio Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001
21 Jan 2021 //
BIOSPACE
AriBio Co.Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001
20 Jan 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.